ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Functional Complete Revascularization as Determined by an Optimized Scoring System After Revascularization: A Post Hoc Analysis from Multi-Center PANDA III Trial.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic value of quantitative flow ratio measured immediately after percutaneous coronary intervention for chronic total occlusion.Journal of geriatric cardiology : JGC · 2025Article
- Functional Complete Revascularization as Determined by an Optimized Scoring System After Revascularization: A Post Hoc Analysis from Multi-Center PANDA III Trial.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Functional complete revascularization (CR) after percutaneous coronary intervention (PCI) as determined by classic residual functional SYNTAX score (c-rFSS) has been associated with improved prognosis. In this study, the c-rFSS algorithm is optimized for a novel modified rFSS (m-rFSS) and prognostic implications of this novel scoring is determined. The m-rFSS algorithm is updated for 2 clinical scenarios, i.e., 1) lesions with suboptimal functional results, and 2) angiographic diameter stenosis <50% but functionally significant stenoses, which are not scored by c-rFSS. The major outcome is a 2-year major adverse cardiac event (MACE). A total of 1,555 patients analyzable for both c-rFSS and m-rFSS are included. After calculating m-rFSS, 12.0% (187/1,555) of patients with c-rFSS-based functional CR (c-rFSS = 0) are reclassified as having m-rFSS-based incomplete revascularization (IR, m-rFSS>0); thus, 377 (21.7%) patients have c-rFSS-based functional IR whereas 524 (33.7%) has m-rFSS-based IR. Patients with m-rFSS-based functional IR (m-rFSS>0) show a significantly higher risk for major MACE outcome (20.8% vs 5.9%; adjusted hazard ratio 3.32, 95% confidence interval: 2.34-4.71) than patients with functional CR (m-rFSS = 0). The m-rFSS is more predictive of 2-year MACE than c-rFSS (difference in C-index 0.07, p < 0.001). In this study, we optimized the classic scoring algorithm to develop a novel scoring system (m-rFSS), and revascularization completeness determined by m-rFSS is markedly associated with a 2-year prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.